MARLBOROUGH, Mass. — Quantiphi, a leading AI-first digital engineering company, engaged in consulting and business transformation services, announced a partnership with Transcell to transform drug discovery and development using artificial intelligence (AI). This partnership combines Transcell’s various innovative platforms in drug discovery and in-vitro neurovirulence/neurotoxicity assessments with Quantiphi’s advanced analytics capabilities to catalyze drug discovery and development processes for faster, more efficient, and safer therapies.
This collaboration is focused on offering AI-driven data integration and optimization strategies to unlock hidden insights from large datasets that originate from wet lab research, clinical research, and patient data. These insights can be used to detect and prevent the occurrence of chronic diseases, accurately identify rare anomalies, assist with in-silico drug discovery, automate manual processes, and engage patients with informed options. The collaboration focuses on supporting improved patient care, outcomes, and improved quality of life.
Quantiphi applies advanced AI tools to help clients reduce the time and resources required for drug discovery, simplify molecular selection processes, predict drug toxicity, and facilitate coordination among pharma and biopharmaceutical translational research programs. Complementary to this, Quantiphi has developed knowledge-mining systems that generate domain-specific insights and streamline research activities.
Transcell offers industry-leading technologies and approaches that contribute to improving the quality of life through personalized medicine. Transcell Oncologics helps improve the precision of novel drugs with focused discovery and development using donor or patient-sourced Biobox technology and predictive models embracing phenomics-inspired decoding mechanisms of action. Transcell Biolife, a fully functional biobank stores donor and patients’ clinical grade progenitor cells (stem cell descendants), derived genetic material and acquired ‘omics data paired with population genetic evidence for advancing transformative medicinal applications.
One fascinating area that Transcell is working on aims to replace the need for live animal testing in parts of the drug and vaccine development and manufacturing process.
“We believe Quantiphi’s passion for solving the most complex problems in life sciences including the creation of alternative methods to replace laboratory animal use in developing new drugs and products matches Transcell group’s vision of translating adult stem cell technology and its prowess to real-time applications. The partnership with Quantiphi will expedite medical research, population genetics, and drug development to achieve improved patient safety by leveraging Transcell's biobanks' ability to collect enormous amounts of human biological material coupled with its de-identified information,” said Dr. S. Dravida, Founder and CEO, Transcell.
“We wholeheartedly support and endorse this alliance to work together promoting discovery processes at reasonable costs and provide alternatives to human/animal drug and vaccine testing. Both the companies bring unique and complementary sets of skills and expertise into this relationship and I am sure we will produce high-value platform-based solutions for the global industry,” said Mr. Uday Chatterjee, Director, Transcell.
“The partnership with Transcell is an exciting opportunity to solve problems that matter. We hope to humanely replace live animal models with intelligent AI-based in-silico options that improve drug quality and testing at dramatically lower price points, which will improve the drug delivery models worldwide,” said Bruno Nardone, Global Head of Healthcare and Life Sciences at Quantiphi, “The strategic relationship with Transcell will bring the best of AI and stem cell technology together as next-generation methodologies to researchers, healthcare professionals, and ultimately patients through the creation of safe vaccines, therapeutics, and more.”
About Quantiphi
Quantiphi is an award-winning AI-first digital transformation engineering company driven by the desire to solve transformation requirements at the heart of the business. Quantiphi solves the toughest and most complex business problems by combining deep industry experience, disciplined cloud and data engineering practices, and cutting-edge artificial intelligence research to achieve quantifiable business impact at unprecedented speed. We are passionate about our customers and obsessed with problem-solving to make products smarter, customer experiences frictionless, processes autonomous and businesses safer by detecting risks, threats, and anomalies. For more on Quantiphi’s capabilities, visit https://quantiphi.com/.
About Transcell
Transcell headquartered in Hyderabad, India is a leading innovation-driven once-in-generation biotech entity developing a portfolio of best-in-class productized offerings by applying for their in-house hypothesis-based discovery and development programs. In Transcell’s universe, the applications are of two types: Therapeutics (www.transcellbio.science residing programs), www.HEMATO.global and www.transcellonco.science) and Non-Therapeutics (www.transtoxbio.com) while the flagship biosamples repository (www.transcell.in) makes it a powerful and compelling journey with the purpose of finding answers for some of the globe's most urgent complex medical needs.
